Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.
Journal Information
Vol. 60. Issue 9.
Pages 565-575 (September 2024)
Vol. 60. Issue 9.
Pages 565-575 (September 2024)
Review Article
New Vaccines for Chronic Respiratory Patients
Visits
1832
Narmeen Mallaha,b,c,d, Ana Dacosta Urbietaa,b,e,f,g, Irene Rivero-Callea,b,e,f,g, Francisco-Javier Gonzalez-Barcalae,g,h,i, Tommaso Bigonij, Alberto Papii, Federico Martinón-Torresa,b,e,f,g,
Corresponding author
a Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), Galicia, Spain
b WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain
c Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBER-ESP), Madrid, Spain
d Department of Preventive Medicine, University of Santiago de Compostela (USC), Galicia, Spain
e Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Galicia, Spain
f Translational Pediatrics and Infectious Diseases Unit, Hospital Clínico Universitario of Santiago de Compostela , Santiago de Compostela, Spain
g Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
h Department of Respiratory Medicine, University Hospital of Santiago de Compostela (CHUS) , Santiago de Compostela, Spain
i Instituto de Investigación Sanitaria de Santiago de Compostela
j Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy
Ver másThis item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Summary of characteristics of RSV vaccines licenced by US Food and Drug Administration and European Medicine Agency for use in adults (as of Septemeber 2023).
Show moreShow less
Abstract
Keywords:
Chronic respiratory diseases
Influenza
Pertussis
Pneumococcal disease vaccine
Respiratory syncytial virus
SARS-CoV-2
Vaccine
Monoclonal antibody
These are the options to access the full texts of the publication Archivos de Bronconeumología